Novel gene therapy solutions for Usher syndrome type I
Usher syndrome type I is a rare, congenital disease characterized by issues in the vestibular system, resulting in deafness, balance issues and blindness. Nawal Ouzren, Sensorion, Montpellier, France, discusses research efforts in treating Usher syndrome type I with gene therapy. Whilst vestibular function has been successfully restored in animal models, further research is required to restore hearing. This interview was conducted during Meeting on the Mediterranean 2022.
Видео Novel gene therapy solutions for Usher syndrome type I канала VJRegenMed
Видео Novel gene therapy solutions for Usher syndrome type I канала VJRegenMed
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
CAR-T trials to watch in ChinaExploring the potential role of CD7-targeting CAR-T cells in T-ALLCurrent developments in cell therapies for solid tumorsTabelecleucel in EBV-associated PTLDChallenges in decentralized manufacturing systemsPiggyBac Transposon-generated CAR T-cells in solid tumorsNerve regeneration with polyhydroxyalkanoate-based conduitsLUMEVOQ gene therapy for LHONHarnessing lipid-specific TCRs to target CD1c-expressing leukemiaEV-based therapies for myocardial infarctionPlasmacytoid dendritic cell-based cancer vaccinesPaige Bischoff, Senior VP, Public Affairs, Alliance for Regenerative MedicineThe changing landscape of hospital-based cell and gene therapy manufacturingIncreasing manufacturing capabilities for gene therapiesDeveloping gene therapies for GJB2 gene related hearing lossProgression of CAR-T trials in ChinaAddressing supply chain issues in clinical trialsIL-1Ra gene therapy for knee OA: interim Phase I resultsEnhancing AAV gene therapy in children with inborn errors of metabolismSPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLSThe past, present and future of AAV vectors